Beijing Beilu Pharmaceutical (300016) — Strategic Asset Allocation Index
Beijing Beilu Pharmaceutical (300016) has a Strategic Asset Allocation Index of 45.1% as of June 2023. Strategic assets (PP&E of CN¥853.80 Million plus long-term investments of CN¥-) total CN¥853.80 Million, measured against net assets of CN¥1.89 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See 300016 equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Beijing Beilu Pharmaceutical Strategic Asset Allocation Index (2006–2021)
This chart shows how Beijing Beilu Pharmaceutical's Strategic Asset Allocation Index has evolved across 16 annual periods from 2006 to 2021. As of June 2023, the index stands at 45.1%, representing strategic assets of CN¥853.80 Million against net assets of CN¥1.89 Billion CNY. For live market cap and overall valuation, see 300016 market cap overview.
Annual Strategic Asset Allocation Index for Beijing Beilu Pharmaceutical (2006–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Beijing Beilu Pharmaceutical from 2006 to 2021, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See 300016 net asset value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 38.1% | CN¥793.92 Million | CN¥793.92 Million | CN¥- | CN¥2.08 Billion | ▼ -1.0 pp |
| 2020 | 39.1% | CN¥739.48 Million | CN¥739.48 Million | CN¥- | CN¥1.89 Billion | ▼ -29.8 pp |
| 2019 | 68.9% | CN¥998.95 Million | CN¥353.26 Million | CN¥645.69 Million | CN¥1.45 Billion | ▲ +3.8 pp |
| 2018 | 65.1% | CN¥784.49 Million | CN¥331.94 Million | CN¥452.54 Million | CN¥1.21 Billion | ▲ +11.1 pp |
| 2017 | 54.0% | CN¥577.23 Million | CN¥283.25 Million | CN¥293.98 Million | CN¥1.07 Billion | ▲ +1.0 pp |
| 2016 | 53.0% | CN¥478.05 Million | CN¥255.87 Million | CN¥222.18 Million | CN¥901.69 Million | ▲ +23.2 pp |
| 2015 | 29.8% | CN¥278.27 Million | CN¥238.54 Million | CN¥39.73 Million | CN¥932.63 Million | ▲ +0.3 pp |
| 2014 | 29.5% | CN¥196.70 Million | CN¥196.70 Million | CN¥- | CN¥666.33 Million | ▲ +0.8 pp |
| 2013 | 28.7% | CN¥160.81 Million | CN¥160.81 Million | CN¥- | CN¥559.38 Million | ▲ +1.6 pp |
| 2012 | 27.2% | CN¥142.33 Million | CN¥142.33 Million | CN¥- | CN¥523.96 Million | ▲ +11.5 pp |
| 2011 | 15.7% | CN¥77.00 Million | CN¥77.00 Million | CN¥- | CN¥491.47 Million | ▲ +2.2 pp |
| 2010 | 13.4% | CN¥62.88 Million | CN¥62.88 Million | CN¥- | CN¥467.62 Million | ▲ +4.8 pp |
| 2009 | 8.6% | CN¥37.45 Million | CN¥37.45 Million | CN¥- | CN¥433.71 Million | ▼ -18.5 pp |
| 2008 | 27.1% | CN¥36.16 Million | CN¥36.16 Million | CN¥- | CN¥133.23 Million | ▼ -15.1 pp |
| 2007 | 42.3% | CN¥38.17 Million | CN¥38.17 Million | CN¥- | CN¥90.33 Million | ▼ -15.0 pp |
| 2006 | 57.3% | CN¥40.99 Million | CN¥40.99 Million | CN¥- | CN¥71.59 Million | — |